fier of cytotoxic damage following immune-mediated inbodies for immunohistochemistry and correlative in situ hyjury to glomerular cells [7] , and that it may contribute bridization, we assessed the intrarenal expression of both to the development of focal segmental glomerulosclero-FGF-2 and FGFR1 in 13 specimens of adult kidney removed sis [8, 9] . Furthermore, FGF-2 exhibits mitogenic actions during tumor nephrectomy.
Results. The FGF-2 expression pattern in the kidneys as on various renal cells, such as mesangial cells [10] [11] [12] , detected by immunohistochemistry was variable and depended glomerular endothelial and epithelial cells [13, 14] , tubuon the antibody used. The most consistent expression of FGF-2 lar epithelial cells [15] , and vascular smooth muscle cells protein was demonstrated in glomerular parietal epithelial [5] . Through its mitogenicity and chemotactic action on cells, tubular cells (mainly of the distal nephron), as well as endothelial and smooth muscle cells, FGF-2 also acts as arterial endothelial cells. These locations also corresponded to areas of FGF-2 mRNA expression. Additionally, by immunoan angiogenic factor [3, 5] .
histochemistry, FGF-2 protein was detected in arterial smooth
Fibroblast growth factor-2 exists in multiple isoforms muscle cells and occasional podocytes. The expression of in the kidney [11] , which arise from alternative splicing.
FGFR1 protein and mRNA was most consistently present in
This alternative splicing determines whether the isotubular cells of the distal nephron and in vascular smooth muscle cells. In situ hybridization, but not immunohistochemisforms localize to the cytoplasm or nucleus [16] . Following try, also suggested FGFR1 expression in cells that could not cellular release, FGF-2 may be sequestered in the extrabe precisely identified within the glomerular tuft as well as cellular matrix by binding to heparan sulfate proteoglysome interstitial cells.
cans (HSPGs) [5] . HSPGs in the cell membrane also act
Conclusion. These data suggest potential autocrine and paras low-affinity receptors for FGF-2 and are necessary acrine pathways within the FGF-2 system, particularly within the vascular walls and in the distal nephron, and thereby profor signaling by this peptide [17] . In addition to HSPG vide information for further mechanistic understanding of the low-affinity receptors, four high-affinity FGF receptors role of the FGF-2 system in human renal disease.
have been identified (FGFR1 to FGFR4), of which FGFR1, FGFR2, and FGFR3 bind FGF-2 [3, 18] . It is controversial as to whether FGFR4 can also bind FGF-2 Fibroblast growth factor-2 (FGF-2; also known as basic [19, 20] . Further complexity is added by the fact that FGF) is a pleiotrophic growth factor with a wide distribu-FGFR1, FGFR2, and FGFR3 each exist as different splice variants (for example, IIIb and IIIc variants), this respect previous studies have yielded controversial unknown. This antibody recognized FGF-2 in steamheated, formalin-fixed sections and in methyl Carnoy's data. FGF-2 expression in adult human kidney has been described as almost absent [21] , largely confined to midfixed, paraffin-embedded sections. FGFR1. Flg/C-15 (Santa Cruz Biotechnology) is an size blood vessels [22] or to tubular cells [23] , present in vessels and cells of Bowman's capsule but not tubules affinity-purified rabbit polyclonal antibody raised against a peptide corresponding to amino acids 808 to 822 map- [24] , or widely expressed in endothelial, glomerular, tubular and medullary interstitial cells [25] . In the case of ping within the intracellular carboxy terminal region of human FGFR1. The antibody recognizes FGFR1 in FGFR1, its expression within the human kidney has also been reported variably, ranging from absent [23] to exmethyl Carnoy's fixed, paraffin-embedded sections. The antibody is nonreactive with FGFR2 (bek), FGFR3, or pression in tubular cells with minimal or negative immunostaining of vessels and glomeruli [26] [27] [28] .
FGFR4, as determined by Western blotting against the purified proteins corresponding to these receptors. In our current study, we reassessed the previously mentioned issues using a combined approach of immuClone VBS1 is a murine monoclonal IgM antibody raised against the extracellular ligand-binding domain of nohistochemistry with multiple antibody preparations, as well as correlative in situ hybridization to describe FGFR1 isolated from bovine coronary venular endothelial cells, as described [30] . The antibody was extensively the localization of FGF-2 as well as FGFR1 in nondiseased adult human kidney. Our data provide a basis characterized previously and shown to specifically immunoprecipitate FGFR1 at 120 kDa [30, 31] . for further mechanistic understanding of the role of the FGF-2 system in human renal disease.
Tubular markers. EMA, clone E29 (Dako, Carpenteria, CA, USA), is a mouse monoclonal IgG2a that is specific for epithelial membrane antigen [38] . It reacts METHODS with normal epithelium in a variety of tissues and has Tissue selection been characterized by comparative immunocytochemistry with several other polyclonal and monoclonal antiMacroscopically normal-appearing human kidney tissue (N ϭ 13) obtained fresh from uninvolved portions EMA antibodies [38] . Rabbit anti-Na,K-ATPase (Upstate Biotechnology of kidneys surgically resected for localized renal cell carcinoma was fixed in 10% neutral-buffered formalin, and Inc., Lake Placid, NY, USA) is a whole rabbit antiserum created against the ␤-1 subunit of rat Na,K-ATPase [39] . was processed and embedded in paraffin according to conventional techniques. Portions of these kidneys were It was characterized with Western blotting. also fixed in methyl Carnoy's solution and were paraffin Immunohistochemistry embedded as previously described [29] . Four micrometer sections of all specimens were stained with the periodic Immunohistochemistry was performed on methyl Carnoy's fixed, paraffin-embedded tissues following a stanacid-Schiff reagent, silver methenamine, and hematoxylin and eosin using conventional techniques for light midard avidin-biotin complex (ABC) method. Briefly, sections were deparaffinized in xylene and rehydrated in croscopy and evaluation of the overall morphology. graded ethanols. Endogenous peroxidase was blocked Antibodies by incubation in 3% hydrogen peroxide. The sections were then incubated for one hour with the primary anti-FGF-2. Basic fibroblast growth factor/147 (bFGF/147; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) body diluted in phosphate-buffered saline (PBS) plus 1% bovine serum albumin (BSA). Following washes in and bFGF/Ab2 (Oncogene Science, Cambridge, MA, USA) are affinity-purified rabbit polyclonal antibodies PBS, the sections were sequentially incubated with biotinylated goat-anti-rabbit or horse-antimouse antibody raised against a peptide corresponding to amino acids 40 to 63 mapping within the amino terminal region of (Vector Labs, Burlingame, CA, USA), the ABC-Elite reagent (Vector Labs), and finally 3,3Ј-diaminobenzidine human FGF-2. Both antibodies recognized FGF-2 in methyl Carnoy's fixed, paraffin-embedded sections.
(DAB; with nickel chloride enhancement) was used as the chromogen. Sections were counterstained with Clone 3H3/Ab3 is a murine monoclonal IgG 1 antibody to human recombinant FGF-2 (Oncogene Science). The methyl green and were dehydrated and cover slipped. Sections of all 13 kidneys were stained with all of the specific FGF-2 epitope(s) recognized by the antibody is unknown. This antibody recognized FGF-2 in steamantibodies. To confirm the staining patterns, all antibodies were also used for immunohistochemistry on acetoneheated, formalin-fixed sections and in methyl Carnoy's fixed, paraffin-embedded sections.
fixed frozen tissue sections. Double immunocytochemistry was performed to deThe fourth antibody, clone DE6, is a murine monoclonal IgG 1 antibody to human recombinant FGF-2 tect FGF-2 expression in combination with the tubular markers, EMA and Na,K-ATPase. Briefly, slides were (kindly provided by Synergen, Boulder, CO, USA). The specific FGF-2 epitope(s) recognized by the antibody is incubated with either AB3 or bFGF/147, peroxidase- conjugated secondary antibody and were reacted with DAB to give a brown colored product. After washing, residual peroxidase blocking with hydrogen peroxide and g/ml (Ab3), or a 1:1000 dilution (DE6), incubated overnormal serum blocking, the slides were then stained with night at 4ЊC, and then employed for immunostaining. the second primary antibody (EMA or Na,K-ATPase),
Further controls in the case of the bFGF/147 antibody biotinylated secondary antibody, ABC-HRP (Vector) included wells coated with the peptide used for immuniand were reacted with Vector VIP peroxidase substrate zation (amino acids 40 to 63 mapping within the amino kit (Vector) to give a purple reaction product.
terminal region of human FGF-2; Santa Cruz) at a conFor all samples, negative controls for the immunohiscentration of 10 or 50 g/ml. Absorbed antisera were tochemical procedures included substitution of the prithen used for repeat immunohistochemical procedures mary antibody with irrelevant murine monoclonal antias otherwise detailed earlier in this article. bodies or nonimmune rabbit antibody or PBS.
In further control experiments, solid-phase preabsorpWestern blotting tion of the anti-FGF-2 antibodies was carried out by coatTo confirm the specificity of the four antibodies against ing recombinant FGF-2 or FGF-1 (both from Oncogene FGF-2 employed for immunohistochemistry, Western Research Products) onto 96-well polystyrene plates overblotting was performed using recombinant human FGF-2 night at 4ЊC in 0.2 m carbonate buffer (pH 9.6) at a concenand FGF-1 (Santa Cruz Biotechnology) and homogenates tration of 2.5 g/ml. Control wells contained buffer only.
of adult human kidney. Kidney samples were prepared Plates were then washed with PBS and blocked with 1% as previously described [8, 12] . Samples were electropho-BSA for one hour at room temperature. Following this, resed on a 15% sodium dodecyl sulfate-polyacrylamide one of the four anti-FGF-2 antibodies was added at a concentration of 1 g/ml bFGF/147, 4 g/ml (Ab2), 0.5 gel (SDS-PAGE) and were then blotted onto 0.2 m a See text for further details nitrocellulose membranes. The blots were blocked with cipitated, resuspended in nuclease-free water containing 10 mmol dithiothreitol, and stored at Ϫ20ЊC. Probes 5% BSA in PBS for one hour and then incubated with primary antibody or an equal concentration of normal were used within 48 hours. Pilot studies were performed with the flg and FGFR1␤ rabbit IgG or monoclonal mouse IgG 1 (Dako) diluted in Tris-buffered saline containing 1% BSA for two hours probes in which the 35 S-UTP-labeled probes were treated to limited alkaline hydrolysis in order to generate fragat room temperature. After washing, the blots were incubated with alkaline phosphatase-conjugated goat antiments of approximately 200 bp. The hydrolyzed and fulllength transcripts were used on replicate sections. The in rabbit IgG or goat antimouse antibody (Dako) for one hour. The blots were then visualized with 5-bromo-4-situ hybridization signal was equivalent with both probes, and the full-length probes were used in subsequent exchloro-3-indolylphosphate-nitro blue tetrazolium (BCIP-NBT).
periments to maintain high hybridization stringency.
In situ hybridization Molecular probes
The following probes were used: (a) a 1300 bp cDNA Kidney tissues, which were fixed in 10% formalin and embedded in paraffin, were deparaffinized following stancorresponding to nucleotides 435 to 1735 of human FGF-2 cloned into pKSϩ Bluescript (kindly provided by I. Drumdard protocol. In situ hybridization was then performed as described previously [32, 33] . Briefly, the sections were mond, Charlestown, MA, USA); (b) pCD115, a 1200 bp flg cDNA corresponding to the region encoding the enwashed with 0.5 ϫ standard saline citrate (SSC) and digested with proteinase K (1 g/ml; Sigma Chemical tire extracellular domain, cloned into the pGEM 1 plasmid (kindly provided by Volkard Lindner, Department
Co., St. Louis, MO, USA) in Tris buffer. Several 0.5 ϫ SSC washes were followed by prehybridization for two of Pathology, University of Washington, Seattle, WA, USA); and (c) a 4 kb cDNA encoding the full-length hours. The hybridizations were started by adding 500,000 cpm of 35 S-labeled riboprobe in 50 l of prehybridization sequence of human FGFR1␤ ligated into the PCR-2 plasmid. All constructs were linearized and transcribed buffer and allowed to proceed overnight at 50ЊC. After hybridization, sections were washed with 0.5 ϫ SSC, into an antisense or sense riboprobe, as described previously [34] . Briefly, the transcription reaction mixture treated with RNase A, washed in 2 ϫ SSC, followed by three high-stringency washes in 0.1 ϫ SSC/Tween 20 contained 1 g cDNA (sense or antisense), [ (Sigma) at 50ЊC, and several 2 ϫ SSC washes. After the tissue was dehydrated and air dried, it was dipped in cytidine 5Ј-triphosphate (CTP) and guanosine 5Ј-triphosphate (GTP), RNAsin, dithiothreitol, Tris, and either NTB2 nuclear emulsion (Eastman Kodak, Rochester, NY, USA) and exposed in the dark at 4ЊC for two weeks. SP6 or T7 polymerase. After 75 minutes, the template DNA was digested by adding DNAse and incubating at After developing, the sections were counterstained with hematoxylin and eosin, dehydrated, mounted, and 37ЊC for an additional 15 minutes. Free nucleotides were separated with a Sephadex G-50 column. The collected viewed. Positive cellular labeling was defined as five or more silver grains concentrated over a single cell. fraction containing labeled probe was then ethanol pre- 
RESULTS
extensively in kidney homogenates; Fig. 1 ) [8] . Each of the antibodies recognized recombinant FGF-2, with a Morphological findings in adult human kidneys major band detected at approximately 18 kDa and a By conventional light microscopy, the adult kidney second weaker band at approximately 36 kDa. None of specimens were, for the most part, morphologically northe antibodies showed cross-reactivity with FGF-1. In mal, although focal areas demonstrating variable degrees addition, the three commercially available antibodies of focal and segmental glomerulosclerosis, tubular atrorecognized several bands in the tissue lysates with apphy, interstitial fibrosis, and arteriosclerotic changes proximate molecular weights of 18, 28, 30, and 36 kDa. were present. These changes were completely consistent
The appearance of multiple FGF-2 variants at these apwith nephrosclerotic changes of aging and were freproximate molecular weights has been previously requently concentrated in the immediate subcapsular corported in both human tissue [34] and cultured cells [12, tex. None of these changes were extensive or indicative 35], and is consistent with the presence of several FGF-2 of a superimposed primary disease process.
isoforms.
In further studies, we investigated the effect of an Characterization of anti-FGF-2 antibodies incubation of the bFGF/147 or Ab2 antibody with an All four antibodies were used in Western blotting exexcess of recombinant human FGF-2 prior to immunoperiments to detect recombinant FGF-1 and recombihistochemistry. Similar to previous reports [36, 37] , this nant FGF-2 ( Fig. 1) . Additionally, the Ab2, Ab3, and did not abolish the positive immunostaining with the bFGF/147 antibodies were used in Western blotting exantibodies but rather resulted in prominent staining of periments using lysates derived from adult kidney cortex tubular basement membranes and adjacent interstitial matrix (data not shown). (the DE6 antibody has previously been characterized with immobilized complete FGF-2 (Fig. 2) . Immunostaining with the Ab2 and DE6 antibodies was moderately reduced but not abolished following incubation with immobilized complete FGF-2 (data not shown). Immunostaining with the bFGF/147 was reduced in samples that were incubated with the immobilized immunizing peptide (partial FGF-2; data not shown). For all antibodies, a control incubation with immobilized FGF-1 instead of FGF-2 yielded a staining pattern that was similar to that observed with nonabsorbed antibody to FGF-2 (data not shown). Furthermore, in most instances, some enhancement of tubular basement membrane staining was noted in those samples that had been incubated with immobilized FGF-2 (Fig. 2) . This suggests that, analogous to the experiments in which antibody was incubated with excess FGF-2 (discussed earlier in this article), some leakage of the immobilized antigen may have occurred, which resulted in subsequent binding of the FGF-2/anti-FGF-2 antibody complex to the sections.
FGF-2 expression in adult human kidneys
Immunohistochemical findings and the findings of in situ hybridization in the kidneys are summarized in Table 1 . The usage of the four different antibodies against FGF-2 yielded staining patterns that were relatively similar, but some important differences evolved with respect to tissue structures exhibiting positivity, as well as to the intracellular localization of immunoreactive FGF-2 (that is, cytoplasmic stain vs. nuclear stain; Table 1 ). No qualitative differences in localization patterns were obtained when frozen, cryostat tissue sections were used in place of fixed tissue sections for the immunohistochemical procedures.
Vasculature. Arterial endothelial cells consistently expressed FGF-2 protein with all four antibodies used (Fig. 3) . Except for the DE6 antibody, which yielded a cytoplasmic signal, all other antibodies localized detectable FGF-2 to the nuclei of the endothelial cells (Fig. 3) . Compared with endothelial cells, the staining intensity in vascular smooth muscle cells of the vascular media was weaker, but in many instances, positive immunostaining of variable degrees was observed (Fig. 3) . Adventitial cells only exhibited immunoreactivity with the DE6 anti- (Fig. 3D) . In atherosclerotic vessels, FGF-2 immuprobe (bright field: A; dark field: B), as well as with a sense probe (C).
noreactivity of variable degrees was noted in vascular
The hybridization signal is confined to the endothelial layer, whereas smooth muscle cells of the neointima with all four antithe signal over medial smooth muscle cells is indistinguishable from background. Arrowheads indicate internal elastic membrane.
bodies. By in situ hybridization, FGF-2 mRNA was detectable in endothelial cells but not in medial or neointimal smooth muscle cells nor adventitial cells of renal arteries (Fig. 4) . Given this observation, we also carried out solid-phase Compared with arterial endothelial cells, the degree preabsorption experiments with the four anti-FGF-2 anof detectable immunostaining was lower in endothelial tibodies. In these experiments, endothelial, tubular, and cells of peritubular capillaries and veins, where it ranged glomerular cell staining was completely abolished when from absent to focally detectable with the four antibodies employed (Figs. 5 and 7) . In situ hybridization also failed the Ab3 monoclonal anti-FGF-2 antibody was incubated to detect FGF-2 mRNA expression in capillary or venous endothelial cells (Fig. 5E ). No staining of the glomerular basement membrane was noted. Staining of podocytes endothelium.
Glomeruli. Within the glomerular tuft, that is, within was inconsistently present with the polyclonal bFGF/147 and the monoclonal DE6 antibody, but rare to absent mesangial and endothelial cells as well as leukocytes of adult kidneys, a variable number of cells displayed immuwith the two other antibodies (Fig. 5) . In contrast, parietal glomerular epithelial cells stained positively using noreactivity with all four antibodies tested (Fig. 5) . Whereas in some cases, the infrequency of the cells sugall four antibodies, albeit with patterns that ranged from cytoplasmic to nuclear localization (Fig. 5) . By in situ gested labeling of circulating or infiltrating leukocytes (Fig. 5A) , it was more widespread with the DE6 antibody hybridization, FGF-2 mRNA was detectable in occasional parietal glomerular epithelial cells only (Fig. 6 ). and consistent with FGF-2 expression in mesangial and FGF-2 protein and mRNA expression was markedly reduced in sclerotic glomeruli (data not shown).
Tubules. By immunohistochemistry using the four antibodies, tubules consistently expressed FGF-2 in adult kidneys (Figs. 5 and 7) . In situ hybridization also confirmed the presence of FGF-2 synthesis in tubular cells (Fig. 8) . A more detailed analysis of the tubular segments was based on morphological criteria to identify tubular ysis revealed that particularly the epithelium of distal tubules, including the macula densa, as well as collecting ducts, exhibited positive immunolocalization (Fig. 7) .
To confirm the localization of FGF-2 in specific tubular Staining patterns within individual cells again were varisegments, double immunohistochemistry was performed able and ranged from cytoplasmic staining (Fig. 7C) to with Ab3 and bFGF/147 in combination with markers exclusively nuclear staining, especially in the case of staining with the AB3 monoclonal antibody (Fig. 7 A, B) .
of distal tubules such as EMA and Na,K-ATPase (Fig. 9) . These experiments demonstrated colocalization of the markers with FGF-2 and thus confirm that FGF-2 is primarily expressed in cells of the distal tubule.
Interstitium. Using the DE6 monoclonal antibody against FGF-2, positive immunostaining was detectable in the interstitium of adult kidneys (Figs. 3D, 5E , and 7C.). Reactivity was weak to absent when the other antibodies to FGF-2 were employed, and only rare cells, which often appeared to represent peritubular capillary endothelial cells, exhibited signal. Staining of the extracellular matrix and/or the tubular basement membrane (Fig. 10) . In focal interstitial infiltrates, the majority membrane of some tubules (arrowheads).
of mononuclear cells failed to exhibit positive immunostaining with three of the four anti-FGF-2 antibodies, whereas the DE6 antibody occasionally yielded positive staining in a high percentage of infiltrating cells (data lems, these cells could not be phenotyped. Their rarity, not shown). By in situ hybridization, only very rare interhowever, would suggest that they did not represent institial cells contained FGF-2 mRNA (data not shown).
trinsic renal cells, but rather infiltrating or circulating leukocytes. As in the case of immunohistochemistry, the Because of the rarity of such cells and technical prob- (Fig. 12 B, C) .
chemistry with
In situ
The signal was usually not detectable at the edge of the anti-FGFR1 hybridization antibody with probe glomerular tuft (Fig. 12 B, C (Fig. 12D ) and expressed FGFR1 mRNA (Fig. 12 B, C) ,
whereas no signal was obtained over Bowman's capsule the cell membrane to diffuse cytoplasmic stain (Fig. 13) .
In the absence of specific immunohistochemical markers of the collecting duct cells, it was not possible to unequivmajority of mononuclear cells in interstitial infiltrates ocally assign FGF-1 expression to either intercalated or did not exhibit detectable amounts of FGF-2 mRNA.
principal cells.
Interstitium. By immunohistochemistry, rare cells in FGFR1 expression in adult kidneys
the interstitium of normal kidneys stained positively for Immunohistochemical findings and the findings of in FGFR1 using either antibody (Fig. 12D) . No staining of situ hybridization in the kidneys are summarized in the extracellular matrix or tubular basement membrane Table 2. was noted. No enhanced staining was noted in areas of Vasculature. Within the arterial vasculature, endotheinterstitial fibrosis. Most leukocytes in focal infiltrates lial cells failed to express FGFR1 in adult kidneys with also failed to express FGFR1 protein, but in some cells, both the polyclonal Flg/C-15 and monoclonal VBS1 antistrong staining was noted. In situ hybridization in normal body (Fig. 11 A, B) . By in situ hybridization with either kidneys demonstrated strong FGFR1 mRNA expression of the two FGFR1 probes, most arterial endothelial cells in some cells of the interstitium, but no enhanced mRNA also did not appear to express mRNA (Fig. 11 C, D) , expression in areas of interstitial fibrosis (Fig. 12 B-C) . but the expression of FGFR1 mRNA in adjacent smooth
As in the case of immunohistochemistry, however, most muscle cells at times rendered the definitive localization cells in mononuclear infiltrates failed to exhibit FGFR1 of grains to specific cell types difficult. Smooth muscle mRNA expression, again suggesting that either a subcells stained positively to a variable degree for FGFR1 fraction of leukocytes and/or rare intrinsic interstitial protein using the two anti-FGFR1 antibodies. Furthercells express FGFR1 mRNA. more, both FGFR1 mRNA and protein were detectable in neointimal lesions in atherosclerotic vessels (Fig. 11  DISCUSSION  B-D) . Vascular adventitia failed to express FGFR1 proUsing an approach that combines multiple antibodies tein or mRNA.
for immunohistochemistry and in situ hybridization, we Capillary and venous endothelium did not express demonstrate intrarenal expression of both FGF-2 and FGFR1 mRNA or protein in normal kidneys.
FGFR1 under all conditions employed. This study is Glomeruli. By immunohistochemistry, most glomerunoteworthy for the heterogeneity of some of the findings. lar cells were unreactive with both of the anti-FGFR1
This contrasts with previous studies on other cytokines antibodies (Figs. 11A and 12A) . Frequently, however, a and their receptors in human kidney, in which we have few individual cells within the glomerular tuft stained used the same approach and obtained consistent protein positively for FGFR1 (Figs. 11A and 12A ). These latter cells often localized to capillary lumina, suggesting that and mRNA data [29, 32, 33, 38, 39] . In the case of FGF-2, it has been reported that fixation conditions have a major ment membranes and the extracellular matrix [37] . This bound exogenous FGF-2 is then labeled in the subseinfluence on the apparent localization of the cytokine within rat kidney [35] and also on the apparent intracelluquent tissue immunohistochemical procedures. However, using Western blots, as well as absorption of the lar localization of FGF-2, that is, localization to nuclear versus cytoplasmic compartments [40, 41] . Although difantibodies to a solid phase, we demonstrate that all four antibodies react specifically with recombinant FGF-2 and ferences in fixatives may account for some of the discrepancies between our in situ hybridization data and immudo not cross-react with FGF-1. We therefore conclude that the different expression patterns of FGF-2 may renostaining results, all material for immunohistology was fixed and processed in the same manner. Consequently, sult from the complexity of the FGF-2/FGFR1 system, particularly its multiple isoforms, and the resulting differthe apparent variability, particularly in the case of FGF-2 expression, must be attributed to differences among the ences in antibody specificities [42] . Furthermore, in the case of FGF-2, it has been described that mRNA expresantibodies employed for immunostaining.
To demonstrate that the different staining patterns sion is much less widespread in comparison to protein expression, which reflects the fact that FGF-2 is mostly with the FGF-2 antibodies were specific, several control experiments were performed. Similar to previous reports stored in the cytoplasm and/or extracellular matrix and synthesized only on demand [43] . Similar considerations [36, 37], we noted that it was not possible to demonstrate specificity of the immunostaining pattern by preabsorpalso apply to FGFR1, where again, the occurrence of different splice variants may result in apparently differtion of the antibodies with excess antigen. Rather, in this case, there is binding of some of the exogenous FGF-2 ent staining patterns. Within glomeruli, the demonstration of FGF-2 protein used in the absorption procedures to HSPGs within base- in a typical mesangial pattern was exceptional in this low translational efficacy in the case of FGFR1. This assumption is consistent with the literature, in which Ford study. This contrasts with findings in rats, where, using comparable conditions (methyl Carnoy's fixed, paraffinet al describe prominent expression of FGFR1 mRNA (with low to absent expression of FGFR2, FGFR3, and embedded tissue, DE6 monoclonal antibody), we noted prominent expression of FGF-2 in mesangial cells in vivo FGFR4 mRNA) in normal rat glomeruli [44] , whereas we and others have reported absent or only minimal [11] . Rather, in the present study, occasional visceral and in particular parietal glomerular epithelial cells were FGFR1 protein expression in both normal rat and human glomeruli [8, 23, 28] . most consistently positive for FGF-2. Similarly, SteinOakley et al, using a different anti-FGF-2 monoclonal Tubular cells, mainly of the distal nephron (distal tubules, collecting ducts), were one of the two sites in which antibody on cryostat, paraformaldehyde-fixed sections, described FGF-2 expression in nuclei of parietal glomerwe consistently detected FGF-2 mRNA and protein under all experimental conditions. Previously, Hughes and ular epithelial cells in normal human kidney [25] . In contrast to FGF-2, the expression of FGFR1 in glomeruli Hall, using a polyclonal anti-FGF-2 antibody (Oncogene Science, NY, USA) in formalin-fixed tissues, as well as in this study was notable for the relative abundance of mRNA transcripts but low intraglomerular expression Stein-Oakley et al also described tubular FGF-2 protein expression without commenting on the specific localizaof FGFR1 protein. Because our anti-FGFR1 antibodies were directed against different portions of the FGFR1, tion [23, 25] . However, in the rat, a detailed study by Cauchi et al using various fixation conditions and two the predominance of a particular splice variant is unlikely to underlie this observation. Rather, our data suggest polyclonal anti-FGF-2 antibodies is consistent with our
In the renal interstitium of adult human kidneys, only rare cells expressed FGF-2 or FGFR1 under most conditions of our study. In contrast to Stein-Oakley et al, we failed to observe increased cell-associated FGF-2 expression in fibrotic areas [25] . Rather, FGF-2 protein in these instances localized to the extracellular matrix and tubular basement membrane, that is, the known extracellular binding sites for FGF-2 [37]. Another interesting observation of our current study was that FGFR1 appeared to label some circulating leukocytes in both the renal interstitium and glomerular capillaries, supporting observations of Kerby et al, who noted FGFR1 protein expression in some interstitial inflammatory cells of rejecting transplants [27] .
Apart from tubular cells, the second intrarenal site at which we most consistently detected intense constitutive expression of FGF-2 mRNA and protein was the arterial endothelium. Less consistently, FGF-2 expression was identified in capillary and venous endothelium, as well as in vascular smooth muscle cells. Using frozen sections, others have detected FGF-2 in the basement membrane of normal human blood vessels and/or occasional capillary endothelial cells [21, 22] . Similar to this study, SteinOakley et al described prominent endothelial expression of FGF-2 in normal human kidney using formalin-fixed, paraffin-embedded material [25] . Combined with our demonstration of FGFR1 expression in vascular smooth muscle cells, where FGFR1 is the predominantly ex- way is supported by several experiments in rats, in which arteries were mechanically wounded and which demonstrate that FGF-2 released from injured cells of the vascular wall mediates smooth muscle proliferation as well as observations in humans, in that FGF-2 immunoreactivity angiogenesis [49-51]. The exogenous administration of was described in the S3 segments of proximal tubules, FGF-2 has also been shown to promote endothelial rethick ascending limbs of the loop of Henle, distal tubules, generation after injury in rats [52] . This suggests that, at and collecting ducts [36] . Our parallel demonstration least in the rat, endothelial cells also express FGFR. of high-level FGFR1 protein and mRNA expression in Our failure to detect FGFR1 on endothelial cells may some, but not all, cells of the distal nephron suggests that therefore relate to low-grade expression in humans or FGF-2 may have an important physiological autocrine suggest that FGFRs other than FGFR1 are predomior paracrine role in the maintenance of tubular and/or nantly expressed on these cells. peritubular functions. The pathophysiological relevance In summary, we describe the renal expression of of FGFR1 expression in these sites is indicated by studies FGF-2 and FGFR1 in mature human kidney. One of the in which chronic, high-dose administration of FGF-2 to important findings of this study is that despite considerrats or cynomolgus monkeys induced tubular dilation able effort, it was not always possible to clarify definiand cast formation [45] . It is also of interest in this context tively whether these proteins, especially FGF-2, are exthat Kanda et al have shown that antagonism of FGF-2 pressed at particular sites. Given the complexity of the in rats with a neutralizing antibody reduced peritubular FGF system, the clarification of these open questions endothelial but not tubular cell proliferation during the may be a difficult task. On the other hand, we provide compensatory growth that follows uninephrectomy [46] . evidence for definitive expression of FGF-2 and FGFR1 Because compensatory growth of tubules is mostly dein the vascular wall and cells of the distal nephron. These rived from proximal tubular cells [47] , these data appear data will serve to explain the pathophysiological role of compatible with our findings, which showed that these cells fail to express FGF-2 and FGFR1.
FGF-2 in health and disease.
